H. pylori: The Bacterium That Overturned 100 Years of Ulcer Medicine, Survives in Gastric Acid Using a Urease Enzyme That Raises Local pH to 5–6, Injects Oncoproteins Into Gastric Epithelium, and Causes Virtually All Peptic Ulcers — and Is Curable in 2 Weeks
Updated: June 2026H pylori · H. pylori symptoms · H. pylori treatment · H. pylori eradication · H. pylori diagnosis · what is H. pylori · Helicobacter pylori · Helicobacter pylori treatment · Helicobacter pylori symptoms · H. pylori stomach ulcer · H. pylori and ulcers · H. pylori peptic ulcer · peptic ulcer disease · stomach ulcer cause · what causes stomach ulcers · peptic ulcer bacteria · Barry Marshall H. pylori · Barry Marshall Nobel Prize · Marshall 1984 H. pylori · Marshall Warren Nobel Prize · Nobel Prize 2005 gastric · H. pylori Nobel Prize · H. pylori history · how H. pylori was discovered · H. pylori drinking experiment · H. pylori urease · urease enzyme · H. pylori acid resistance · how H. pylori survives stomach acid · urease stomach pH · ammonia stomach H. pylori · H. pylori gastric acid · CagA virulence factor · CagA H. pylori · cytotoxin associated gene A · H. pylori virulence · H. pylori carcinogen · H. pylori tight junctions · H. pylori epithelial · H. pylori inflammation · H. pylori gastritis · chronic active gastritis · H. pylori NF-kB · H. pylori IL-8 · H. pylori cancer · H. pylori gastric cancer · H. pylori stomach cancer · H. pylori gastric adenocarcinoma · gastric cancer risk H. pylori · H. pylori 10x cancer risk · H. pylori MALT lymphoma · H. pylori lymphoma · H. pylori triple therapy · triple therapy H. pylori · H. pylori antibiotics · H. pylori treatment protocol · PPI clarithromycin amoxicillin · proton pump inhibitor H. pylori · omeprazole H. pylori · H. pylori 14 days treatment · H. pylori eradication rate · H. pylori treatment success rate · clarithromycin resistance H. pylori · H. pylori antibiotic resistance · quadruple therapy H. pylori · bismuth quadruple therapy · H. pylori test stool antigen · stool antigen test H. pylori · H. pylori breath test · urea breath test H. pylori · H. pylori blood test · H. pylori endoscopy biopsy · rapid urease test H. pylori · H. pylori test before treatment · H. pylori test to confirm eradication · H. pylori reinfection · H. pylori transmission · how H. pylori spreads · H. pylori fecal oral · H. pylori water contamination · H. pylori prevalence · how common is H. pylori · H. pylori worldwide · H. pylori developing countries · H. pylori risk factors · H. pylori developing world · H. pylori children · H. pylori family · H. pylori gut microbiome · H. pylori post-eradication microbiome · H. pylori probiotics · probiotics H. pylori treatment · Lactobacillus H. pylori · mastic gum H. pylori · mastic gum stomach ulcer · natural H. pylori treatment · sulforaphane H. pylori · broccoli sprout H. pylori
In 1983, Barry Marshall and Robin Warren submitted a paper to The Lancet proposing that a spiral bacterium they had cultured from gastric biopsies — Helicobacter pylori — was the causative agent of peptic ulcer disease. The paper was rejected. The prevailing consensus for over a century was that the stomach's acid environment (pH 1–2) was too hostile for any bacterium to survive; ulcers were attributed to stress, spicy food, excess acid, and — most influentially — individual psychological constitution. The suggestion that ulcers were an infectious disease seemed absurd to most gastroenterologists. To prove it, Marshall cultured H. pylori from a biopsy, drank the culture, and developed acute gastritis within days. He documented it by endoscopy and biopsy. He treated himself with antibiotics and recovered. In 2005, Marshall and Warren received the Nobel Prize in Physiology or Medicine. The entire model of peptic ulcer disease, three decades of anti-ulcer pharmaceutical strategy (cimetidine, ranitidine — blockbuster H2 blockers sold for "stress-related" acid hypersecretion), and billions in revenue had been built on a wrong premise.
H. pylori is now established as the single most important infectious carcinogen in the world — classified as a Group 1 carcinogen (definite human carcinogen) by the International Agency for Research on Cancer (IARC) — because persistent H. pylori infection increases the risk of gastric adenocarcinoma by approximately 10-fold. Gastric cancer is the fifth most common cancer globally and the fourth most common cause of cancer death; approximately 75–89% of non-cardia gastric adenocarcinomas are attributable to H. pylori. The bacteria is present in approximately 44% of the global population (higher in developing countries; declining in developed countries due to improved sanitation), meaning several billion people carry a known carcinogen in their stomach — the majority undiagnosed.
44%
global H. pylori prevalence (Hooi 2017) — Hooi et al. 2017 (Gastroenterology): systematic review and meta-analysis of H. pylori prevalence; 62 countries included; global prevalence: 44.3% of the world population; regional variation: Africa: 70.1%; South America: 63.4%; Asia: 54.7%; Eastern Europe: 55.7%; Western Europe: 34.3%; North America: 37.1%; Australia/New Zealand: 24.4%; developed nations have seen significant declines in prevalence over the 20th century due to: improved sanitation and clean water supplies; reduced household crowding; improved childhood nutrition (malnutrition impairs gastric acid production, facilitating H. pylori colonization); trends: prevalence declining in developed countries but increasing infection "backlog" in middle-income countries as they urbanize; most infections are acquired in childhood (H. pylori is almost never a new adult acquisition); transmission: fecal-oral route (contaminated water, inadequate hand hygiene) and oral-oral route (saliva — explaining familial clustering); the practical implication of 44% global prevalence: H. pylori testing should be considered for any adult with: unexplained dyspepsia; iron deficiency anemia without obvious cause (H. pylori impairs iron absorption); new epigastric pain; family history of gastric cancer; before starting long-term NSAIDs (which dramatically worsen H. pylori-associated ulcer risk)
Urease
how H. pylori survives gastric acid — the human stomach maintains a luminal pH of approximately 1–2 — a pH that kills virtually all ingested bacteria within minutes; H. pylori has evolved a remarkable acid-survival mechanism: urease enzyme; urease is a nickel-containing enzyme that catalyzes the hydrolysis of urea to ammonia (NH₃) and carbon dioxide (CO₂): Urea → NH₃ + CO₂; ammonia is a base (pKa 9.25) that rapidly neutralizes local acid; the result: H. pylori creates a microenvironment immediately surrounding itself at pH 5–6 — survivable but not lethal; H. pylori also produces a motility-driven corkscrew motion that allows it to penetrate the mucus layer and adhere to gastric epithelial cells (avoiding the most acid-exposed lumen); the urease mechanism has practical importance: it is the basis of all urease-based H. pylori tests; urea breath test (UBT): patient drinks ¹³C-labeled urea; if H. pylori urease is present, labeled CO₂ appears in exhaled breath (specific and sensitive, ~95% each); rapid urease test (CLO test, Campylobacter-Like Organism test): endoscopic biopsy placed in urea-containing gel; color change in minutes if urease present; stool antigen test: detects H. pylori antigens in stool; sensitivity ~94%, specificity ~97%; all non-invasive tests require stopping PPIs 2 weeks before and antibiotics 4 weeks before (PPIs suppress urease activity, causing false negatives)
CagA
the oncogenic virulence factor — approximately 60–70% of H. pylori strains carry the cag pathogenicity island (cagPAI) — a genomic island of ~40 genes encoding a type IV secretion system (T4SS); T4SS is essentially a molecular syringe that injects the CagA (cytotoxin-associated gene A) protein directly into gastric epithelial cells; once inside, CagA is phosphorylated by SRC-family kinases at EPIYA motifs; phosphorylated CagA activates multiple oncogenic pathways: SHP-2 tyrosine phosphatase activation → hummingbird phenotype (elongated cell morphology); β-catenin nuclear translocation → WNT signaling activation → epithelial proliferation; NF-κB activation → IL-8, TNF-α, IL-6 release → chronic inflammation; E-cadherin disruption → tight junction breakdown → increased intestinal permeability; p53 suppression → reduced apoptosis of damaged cells; the cancer sequence (Correa cascade): H. pylori → chronic gastritis → atrophic gastritis → intestinal metaplasia → dysplasia → gastric adenocarcinoma; this progression takes decades; CagA+ strains: associated with higher rates of peptic ulcer disease, gastric cancer, and MALT lymphoma vs CagA- strains; IARC: H. pylori classified as Group 1 carcinogen in 1994; the 10× gastric cancer risk in H. pylori-positive individuals relative to H. pylori-negative individuals is well-established; eradication reduces this risk by approximately 35–40% and completely prevents progression in pre-cancerous stages
70–85%
triple therapy eradication rate — standard triple therapy for H. pylori eradication: proton pump inhibitor (PPI) + clarithromycin + amoxicillin × 14 days; PPI (omeprazole 20mg, lansoprazole 30mg, or pantoprazole 40mg): suppresses acid → raises gastric pH → dramatically increases antibiotic stability and effectiveness (clarithromycin is acid-labile — degrades rapidly at low pH); clarithromycin 500mg BID (a macrolide antibiotic that inhibits bacterial protein synthesis at the 50S ribosome); amoxicillin 1g BID (a beta-lactam that inhibits cell wall synthesis); historical eradication rates: 70–85% with 14-day triple therapy; the declining eradication rate problem: clarithromycin resistance is the single largest driver of triple therapy failure; global clarithromycin resistance in H. pylori: 20–30% in Western Europe and North America; >40% in Southern Europe and Asia; in high-resistance regions, empiric triple therapy may achieve only 60–70% eradication — below the clinical threshold of acceptable; current guidelines: culture and sensitivity testing or PCR resistance testing before prescribing antibiotics is increasingly recommended; alternative first-line regimens in high-resistance areas: bismuth quadruple therapy (bismuth + metronidazole + tetracycline + PPI × 14 days): 85–95% eradication regardless of clarithromycin resistance; concomitant therapy (PPI + clarithromycin + amoxicillin + metronidazole): 90%+ eradication
Ready to fix this at the root?
The 30-Day Gut Reset is the full day-by-day protocol — mechanisms, dosed repair steps, a diagnostic chapter, food/swap tables, and a maintenance plan, built from the same research on this page.
Get the Gut Reset → $19
H. pylori Testing and Eradication Protocols
| Test | Method | Sensitivity / Specificity | Use Case | Notes |
|---|
| Urea Breath Test (UBT) | Drink ¹³C-urea; measure exhaled ¹³CO₂ | ~95% / ~95% | Initial diagnosis; confirmation of eradication | Stop PPIs 2 weeks, antibiotics 4 weeks before; gold standard non-invasive |
| Stool Antigen Test | ELISA for H. pylori antigens in stool | ~94% / ~97% | Initial diagnosis; eradication confirmation | Same PPI/antibiotic hold; monoclonal antibody tests more accurate than polyclonal |
| Endoscopy + Biopsy (CLO) | Biopsy placed in urease gel; color change | ~90% / ~95% | When endoscopy indicated (alarm symptoms, age >60) | Allows culture + sensitivity testing; most informative but invasive |
| Serology (IgG antibody) | Blood test for H. pylori IgG | ~85% / ~79% | Epidemiological screening only | Cannot distinguish active vs past infection; NOT suitable for eradication confirmation |
Complete H. pylori Management Protocol
Testing indications: test if: unexplained dyspepsia (burning, aching epigastric pain, especially before meals or relieved by eating); known peptic ulcer or history of peptic ulcer; unexplained iron deficiency anemia; idiopathic thrombocytopenic purpura (H. pylori can trigger immune-mediated platelet destruction — eradication resolves it in ~50% of cases); first-degree relative with gastric cancer; before long-term NSAID use (NSAIDs + H. pylori: dramatically synergistic for ulcer risk); do NOT use serology for testing — it cannot confirm active infection or eradication; use urea breath test or stool antigen test.
Treatment (consult your gastroenterologist — antibiotics require prescription): check local clarithromycin resistance rates; if <20% resistance in your region: standard triple therapy × 14 days (PPI BID + clarithromycin 500mg BID + amoxicillin 1g BID); if ≥20% resistance OR previous macrolide exposure: bismuth quadruple therapy × 14 days (PPI BID + bismuth subsalicylate 525mg QID + metronidazole 250mg QID + tetracycline 500mg QID); penicillin allergy substitute: replace amoxicillin with metronidazole; confirm eradication: test at 4–8 weeks after completing antibiotics using UBT or stool antigen — NOT serology; take the full course; most treatment failures are from incomplete antibiotic courses or unrecognized resistance.
Post-eradication gut recovery: triple therapy kills H. pylori but also disrupts the broader gut microbiome (collateral damage from broad-spectrum antibiotics); post-eradication: Lactobacillus rhamnosus GG or VSL#3 probiotic concurrent with and for 4 weeks after antibiotic course — reduces diarrhea, bloating, and microbiome disruption (several RCTs support adjunctive probiotic use during H. pylori therapy); mastic gum 1g BID: resin from Pistacia lentiscus; Huwez 1998 (NEJM letter): in vitro bactericidal activity against H. pylori; small clinical trials show modest eradication rates as monotherapy — NOT adequate as primary treatment but may be useful for ongoing gastroprotection; sulforaphane from broccoli sprouts: Haristoy 2003 and Yanaka 2009: sulforaphane has direct bactericidal activity against H. pylori and reduces gastric colonization — as adjunct or for asymptomatic carriers not yet treating with antibiotics.
H. pylori Test Kit →
Mastic Gum →
As an Amazon Associate, GutCode earns from qualifying purchases made through links on this page. This does not affect the price you pay.